Hutch News

Hutch News

Stories tagged 'pembrolizumab'

For cancer patients with HIV, immunotherapy appears safe

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials

Nov. 7, 2017 | By Mary Engel / Fred Hutch News Service

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.

View story >


How cancer fools healthy neighboring cells

‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients

July 18, 2017 | By Rachel Tompa / Fred Hutch News Service

Like tiny con men, cancer cells have many tricks to fool healthy cells into helping them. Research into the "tumor microenvironment" is uncovering new avenues for treatment.

View story >


A new blood test detects recurrence of rare skin cancer

$200 assay can accurately signal return of Merkel cell carcinoma — in some cases catching tumors earlier than expensive imaging

Dec. 12, 2016 | By Rachel Tompa / Fred Hutch News Service

Fred Hutch and UW researchers have developed an inexpensive blood test to catch recurrences of Merkel cell carcinoma -- in some cases the tests finds tumors earlier than traditional imaging.

View story >


Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.